Publication
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (8)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 8
- cancerHER2-Positive Breast Carcinomacivic_curation1.00
- cancerMalignant Breast Neoplasmcivic_curation1.00
- drugPalbociclibcivic_curation1.00
- drugTrastuzumabcivic_curation1.00
- geneCCND1civic_curation1.00
- geneERBB2civic_curation1.00
- variantCCND1 Amplificationcivic_curation1.00
- variantERBB2 Amplificationcivic_curation1.00
Curated evidence
Evidence citing this paper (2)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 19874578
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ERBB2 Amplification1 | ||||||||
| Palbociclib + TrastuzumabCombination | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID1561In a panel of 47 breast cancer cell lines, HER2 overexpressing cells were among those more sensitive to CDK4/6 inhibitor Palbociclib (PD0332991). In the trastuzumab sensitive cell line Bt474, palbocic… (full text at CIViC) PMID 19874578 · Finn et al., 2009 · Open in CIViC | civic |
| CCND1 Amplification1 | ||||||||
| Palbociclib | Malignant Breast Neoplasm | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID1562A panel of 47 breast cancer cell lines was tested for sensitivty/resistance to CDK4/6 inhibitor Palbociclib (PD0332991), where IC50 below 150nM was sensitive, and above 1000nM resistant. Cyclin D1 ha… (full text at CIViC) PMID 19874578 · Finn et al., 2009 · Open in CIViC | civic |